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The Evidence for Exercise-induced Inflammation in Intermittent 
Claudication: Should we Encourage Patients to Stop Walking? 
P. V. Tisi and C. P. Shearman 
Department of Vascular Surgery, Southampton General Hospital, Southampton, U.K. 
Objectives: To review clinical and experimental evidence that exercise to the onset of calf pain in patients with intermittent 
claudication results in an inflammatory response, and to consider whether epeated inflammatory events induced by 
therapeutic exercise training may lead to progression of atherosclerosis. 
Methods: A literature search was performed to identify studies measuring biochemical markers of exercise-induced 
ischaemia-reperfusion njury in patients with intermittent claudication. Current theories of atherogenesis were reviewed 
and the use of acute-phase proteins as potential markers of vascular disease xplored. 
Results: Exercise to the onset of calf pain results in an inflammatory response with free radical formation, neutrophil 
activation and systemic vascular endothelial damage. Acute-phase proteins such as C-reactive protein and serum amyloid 
A protein have exciting potential use as stable biochemical markers of disease in claudication. 
Conclusions: Further studies are needed to determine the effect of long-term exercise training on exercise-induced 
inflammation i  claudication. Early work suggests, in fact, that exercise attenuates this inflammatory response. If this 
were confirmed then it would support he clinical impression that exercise training is beneficial in terms of symptomatic 
improvement and cardiovascular health in patients with intermittent claudication. 
Key words: Intermittent claudication; Ischaemia-reper)qlsion, Exercise, Acute-phase proteins. 
Introduction 
The usual advice given to a patient with stable in- 
termittent claudication is to "stop smoking and keep 
walking". ~In the general population, regular exercise 
can decrease the risk of future cardiovascular disease 
and improve health. 2'3 In view of this, increased phys- 
ical activity has been promoted as a strategy to improve 
the health of the nation. 4For patients with intermittent 
claudication, exercise undoubtedly has significant 
benefit in terms of reduction of cardiovascular risk 
factors, optimised structural and metabolic per- 
formance of skeletal muscle, improvement in rheo- 
logical parameters, development of collaterals, 
improved walking technique and marked psy- 
chological benefit. 5 Exercise training programs have 
been widely reported in the literature over the past 
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30 years, although few of these studies have been well- 
designed randomised-controlled trials. 6-~° A recent 
meta-analysis of 21 exercise training programmes 
showed that training for at least 6 months by walking 
to near-maximum pain tolerance produced significant 
improvements in pain-free and maximum walking 
distances. 1~Supervised exercise training has also been 
shown to be more effective than percutaneous trans- 
luminal angioplasty in terms of walking distance up 
to 12 months following randomisation. 12 However, 
there was no significant difference between the two 
treatment modalities at 6 years' follow-up. ~3 
In the face of this impressive vidence regarding 
the efficacy of exercise training in claudication, why 
has exercise not been adopted universally as a first- 
line treatment? Although locally benign, intermittent 
claudication is associated with a 10-year mortality 
of at least 50%, predominantly from cardiovascular 
disease. 14This corresponds to 3.8 times the relative 
risk of death compared to a control population. ~5 Evid- 
ence is accumulating that exercise itself may be re- 
sponsible for adverse inflammatory changes, which 
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Fig. 1. Outline of ischaemia-reperfusion injury in intermittent clau- 
dication. (ODFR = oxygen-derived free radicals, LDL = low-density 
iipoprotein). 
may be implicated in this excess cardiovascular mor- 
tality. In 1924, Buerger perhaps recognised this prob- 
lem and suggested that walking for great distances 
should be avoided in claudicants. 16Instead, he pro- 
posed that passive exercises, such as alternate dis- 
tension and emptying of the peripheral circulation by 
leg elevation and dependency should be used to treat 
claudication. Should we therefore encourage our 
patients to exercise to the onset of calf pain? This article 
will explain the putative underlying mechanisms of 
exercise-induced inflammation in claudication and at- 
tempt to rationalise the use of exercise as a treatment 
for intermittent claudication. 
Biochemical basis of ischaemia-reperfusion njury 
The systemic effects of intermittent claudication may 
be subsequent to the phenomenon of ischaemia-re- 
perfusion injury (IRI). The underlying biochemical 
pathways are outlined in Fig. 1. IRI causes greater 
tissue damage from restoration of the blood supply 
following a period of ischaemia than from the original 
ischaemic injury. 17'~s Claudicants experience repeated 
episodes of calf muscle pain on exercise (ischaemia) 
followed by rest (reperfusion). Transient muscle isch- 
aemia is difficult to assess clinically. A reduction in 
transcutaneous oxygen tension (TcPO2) in skin over 
the calf muscle following exercise may, however, reflect 
underlying ischaemic hanges. 19 During muscle isch- 
aemia, inadequate oxidative phosphorylat ion leads 
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Fig. 3. The role of oxygen radicals in vascular disease. (SOD= 
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density lipoprotein). 
to a fall in tissue adenosine triphosphate l vels and 
accumulation of hypoxanthine (Fig. 2). 
Physiologically, xanthine dehydrogenase (XD) in 
vascular endothelial cells converts hypoxanthine to 
xanthine using nicotine adenine dinucleotide as a co- 
factor. Hypoxia induces a calcium-induced protease 
attack on XD forming xanthine oxidase (XO) - the "D- 
O conversion". 2° XO requires oxygen as a co-factor 
which is provided on reperfusion, generating the 
superoxide radical. Superoxide is also a product of 
the "respiratory burst" of activated neutrophils via 
oxidation of nicotinamide adenine dinucleotide phos- 
phate. 21 
Oxygen-derived free radicals (ODFR) are important 
in the pathogenesis of vascular endothelial injury fol- 
lowing ischaemia-reperfusion (Fig. 3). Superoxide in- 
creases intracellular calcium concentration, which 
activates endothelial phosphol ipase A2. This liberates 
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arachidonic acid from membrane phospholipids, 
which is the precursor for pro-inflammatory (thom- 
boxane A2 and leukotriene B4) and anti-inflammatory 
(prostacyclin) eicosanoids. Thromboxane A2 (TXA2) 
causes vasoconstriction, platelet aggregation, pro- 
motes neutrophil chemotaxis and increases vascular 
permeability by disassembling actin microfilaments 
and widening interendothelial tight junctions. 22 Ac- 
tivated neutrophils are probably the main source of 
TXA2 in IRI. Leukotriene B~ (LTB4) is chemotactic for 
neutrophils and upregulates neutrophil-encothelial 
adhesion in the post-capillary venule, leading to an 
increase in microvascular permeability. Animal ex- 
perimental work using eicosanoid receptor antagonists 
has confirmed that these mediators are certainly im- 
portant in acute limb ischaemia 23and therefore may 
perhaps have a role in claudication. 
In vivo, superoxide rapidly dismutates to hydrogen 
peroxide, which may oxidatively damage protein. The 
highly reactive hydroxyl radical is released from hy- 
drogen peroxide in the Fenton reaction, catalysed by 
ferrous ions. 24 It attacks polyunsaturated fatty acid 
side-chains in membrane phospholipids forming the 
peroxyl radical, which initiates a destructive chain 
reaction of lipid peroxidation. This obviously causes 
structural damage to the vascular endothelium, 2s but 
perhaps more importantly in claudication may be 
implicated in progression of atherosclerosis. 
Activated neutrophils play an important role in the 
pathogenesis of ischaemia-reperfusion injury and in 
the extreme situation e.g. acute limb ischaemia, may 
initiate significant systemic pathology such as adult 
respiratory distress syndrome 26'21 and multi-system 
organ failure. R7'28 Neutrophils exert their effects by 
physical obstruction of capillaries (the "no reflow" 
phenomenon), adhesion to the post-capillary venule 
endothelium and release of ODFR, eicosanoids and 
proteases. Neutrophil elastase, in particular, causes 
marked damage to the endothelial basement mem- 
brane, resulting in an increase in microvascular per- 
meability, a9 The precise mechanism of neutrophil 
activation has not been fully clarified. It has been 
suggested that neutrophils are activated locally by 
metabolites released from ischaemic reperfused tissue, 
such as ODFR, TXA2 and LTB,. 30 IRI also leads to 
complement activation, releasing C5a which is chemo- 
tactic for neutrophils. 3~Activated neutrophils are less 
deformable than inactive cells as a result of increased 
cytoplasmic rigidity and projection of pseudopodia, 
and are therefore l ss able to pass through the capillary 
network. 32 This prolonged capillary transit time in- 
creases neutrophil-endothelial binding via the Mac-1 
(CD11b/CD18) cell surface adhesion molecule, which 
is essential for neutrophil-mediated injury and re- 
cruitment of further neutrophils to the site of in- 
flammation. 
Contrary experimental evidence has also suggested 
that a circulating "neutrophil activator" is released 
from ischaemic reperfused tissue, activating systemic 
neutrophils which then plug the capillary network. In 
support of this, Paterson used an ex vivo chemotactic 
model, in which human reperfusion plasma obtained 
from aortic aneurysm surgery activated neutrophils in 
a rabbit dermabrasion lesion, resulting in increased 
microvascular permeability, as Interleukin-8 (IL-8), 
which is synthesised by monocytes in response to 
interleukin-1 and tumour necrosis factor-a, has been 
suggested as the main neutrophil activator. 33IL-8 acts 
specifically on neutrophils promoting chemotaxis, 
neutrophil-endotheial adhesion, extravascular ac- 
cumulation at the site of injury and release of ODFR 
and proteases. 3. 
Current evidence suggests that IRI has important 
effects on endothelial nitric oxide synthesis. Endo- 
thelium derived relaxing factor (EDRF) was isolated 
by Furchgott and Zawadzdki 35, who demonstrated 
that endothelium was essential for the vasodilator 
action of acetylcholine. EDRF was subsequently shown 
to be identical to nitric oxide (NO). 36 NO is synthesised 
from L-arginine by NO synthase (NOS), which exists 
in several isoforms. These are broadly grouped into 
constitutive (cNOS) and inducible (iNOS) enzymes. 
cNOS is found in endothelial cells and platelets, and 
is continuously expressed in response to shear stress, 
histamine, thrombin, bradykinin and acetylcholine. 
The physiological effects of NO are potent vaso- 
dilatation and inhibition of both platelet aggregation 
and neutrophil adhesion. NO synthesis results in a 
basal vasodilatory tone which is synergistic with pro- 
stacyclin. 37Experimental evidence suggests that in 
atherosclerosis there is failure of NO-mediated vaso- 
dilatation: both superoxide generated by IRI and ox- 
idised LDL can inactivate NO. 38'39 Repetitive low-grade 
IRI, as with intermittent claudication, may result in a 
vascular endothelium in which NO-mediated re- 
laxation is ineffective. 39 
iNOS is synthesised by neutrophils, macrophages, 
vascular endothelial and smooth muscle cells (ie. the 
whole vascular wall) in response to inflammatory 
mediators uch as IL-1 and TNF-<,. iNOS produces 
significantly greater quantities of NO than cNOS (1000- 
fold) 38 which may have marked inflammatory effects, 
leading to an increase in vascular permeability. 37 In the 
absence of L-arginine, iNOS may generate superoxide 
which potentiates the inflammatory response. 3sNO 
may also react with superoxide to form the cytotoxic 
peroxynitrite radical. 4° 
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Endothelin may also be involved in the pathogenesis 
of IRI. Endothelin-1 (ET-1) is synthesised by vascular 
endothelial ceils in reponse to ischaemia, shear stress, 
thrombin, angiotensin II, cytokines and IL-I: en- 
dothelin synthesis is inhibited by increased NO syn- 
thesis. *~'~2 The net balance between endothelin-induced 
vasoconstriction a d NO-mediated vasodilatation has 
marked effects on the vascular endothelium. En- 
dothelin itself induces endothelium to synthesise NO, 
suggesting that a fine homeostatic mechanism exists 
in the control of vascular tone. 42 There is evidence that 
synthesis of endothelin-1 increases during reperfusion 
of ischaemic tissue. Edwards et al. 43 reported a canine 
model of aortic cross-clamping in which ischaemia led 
to an insignificant increase in ET-1, with a subsequent 
significant increase in ET-1 on reperfusion. This per- 
haps should be explored in lesser grades of IRI such 
as in claudication. 
Evidence for ischaemia-reperfusion njury in claudication 
Oxygen-derived free radicals. Demonstrating ODFR syn- 
thesis in claudicants i  notoriously difficult, as ODFR 
are highly reactive intermediates with short half-lives. 
Many studies have therefore concentrated on measure- 
ment of stable end products of ODFR-induced lipid 
peroxidation, such as malondialdehyde. Hickman ex- 
ercised 15 claudicants to maximum calf pain and 
demonstrated a significant increase in plasma ma- 
londialdehyde and thrombomodulin (an endothelial 
membrane glycoprotein released with cell damage) 
at 1 rain post-exercise with insignificant changes in 
healthy controls. 44 The claudicants had significantly 
lower resting red cell superoxide dismutase than con- 
trols, suggesting that the free radical scavenging sys- 
tems are also ineffective. 45In a further study, lipid 
peroxides were measured in 10 claudicants and 10 
controls,46 Claudicants had slightly higher resting lipid 
peroxide levels than control subjects, but showed a 
53% increase following maximal treadmill exercise, 
with no change in controls. In a further study, Stringer 
showed an increase in resting lipid peroxides in 50 
patients with arteriographic evidence of peripheral 
vascular disease, compared to a control population. 47 
A further method of assessing ODFR formation is 
to measure individual antioxidant mechanisms, which 
scavenge newly formed ODFR, attenuating the harm- 
ful effects. Glutathione peroxidase (which detoxifies 
hydrogen peroxide) and its co-factor selenium are 
significantly lower following exercise in claudicants 
as compared to control subjects. 48Perhaps a more 
appropriate measure of free radical activity is to assess 
the total antioxidant consumption, as this is in- 
dependent ofthe various metabolic pathways of ODFR 
generation and degradation. Khaira used an enhanced 
chemiluminescent assay to look at exercise-induced 
changes in antioxidant capacity in 20 claudicants and 
nine matched controls. 49 Antioxidant levels in clau- 
dicants (mean 479 ~tmol/1) and controls (438 ~xmol/1) 
were similar at rest, while the claudicants howed 
a significant decrease at i min following treadmill 
exercise (428 ~tmol/1), returning to baseline at 10 min. 
Control subjects howed an insignificant increase in 
antioxidant levels, probably reflecting a protective 
mechanism against he deleterious effects of exercise. 
Neutrophil activation. Accumulating experimental evi- 
dence confirms the importance of neutrophils in skel- 
etal muscle ischaemia-reperfusion. Crinnion, using a 
rat hindlimb ischaemia model, demonstrated that pre- 
treatment with a monoclonal antibody to Mac-1 
neutrophil adhesion molecule prevented neutrophil 
recruitment to the site of injury, attenuated muscle 
necrosis and improved post-ischaemic muscle per- 
formance, soThis experimental situation is more suited, 
however, to revascularization after a period of acute 
limb ischaemia rather than claudication. As discussed 
above, activated neutrophils are larger and stiffer than 
their inactive counterparts. Neumann reported astudy 
in which 17 claudicants exercised using repetitive toe 
stands. 32 Immediately following exercise there was an 
increased neutrophil count in femoral-venous blood 
(local) compared to femoral-arterial b ood (systemic), 
an increased proportion of activated neutrophils and 
decreased neutrophil filtration through 8~tm mi- 
cropore filters (indicative of the decreased de- 
formability of activated neutrophils). After 10min 
these changes were seen in systemic blood. Decreased 
neutrophil filterability in systemic venous blood fol- 
lowing treadmill exercise has also been shown to 
correlate with increased serum lysozyme resulting 
from neutrophil degranulation. 5~ This suggests that 
activated neutrophils are released locally from the 
site of injury into the systemic irculation following 
treadmill exercise. Edwards 48 also showed an increase 
in systemic neutrophil count following exercise. The 
median neutrophil count was 5.6 x 106/1 at rest (com- 
pared to 2.8 x 106/1 in controls), increasing to 7.1 x 106/ 
1 immediately after exercise (p<0.05) and returning to 
baseline at 15 min. A more sophisticated method of 
assessing neutrophil activation has recently been de- 
scribed. 52 The cell transit analyser measures neutrophil 
flow through 8 ~m pores, analysing 1000 cells per 
sample. This study showed that claudicants had an 
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increase in the median and 90th percentile transit ime 
5 min following exercise, with no significant change 
in controls. The change in median transit correlated 
with an increase in plasma thromboxane, adding sup- 
port to the idea that activated neutrophils are the main 
source of thromboxanes in reperfusion i jury. 
Thromboxane synthesis. Limited studies have looked at 
the effect of treadmill exercise on eicosanoid synthesis 
in claudicants. Wennmalm found a significant increase 
in urinary excretion of thromboxane B2 metabolites 
20 min following maximal treadmill exercise in clau- 
dicants. ~3 In another study the resting plasma throm- 
boxane was not significantly different in 11 claudicants 
(median 32.1pg/ml) compared to seven controls 
(25.0 pg/ml). However, following treadmill exercise 
only claudicants showed a significant increase which 
peaked at 15 min (135.0 pg/ml). 48 Khaira also dem- 
onstrated an increase in TXB2 within 10 min of tread- 
mill exercise in claudicants, peaking at 60 min. ~2 A 
similar rise was also seen in controls, although at all 
times levels in claudicants were significantly higher 
than in controls. 
Vascular endothelial damage. The end-result of isch- 
aemia-reperfusion njury in claudication is damage to 
the target organ - vascular endothelium - reflected by 
an increase in systemic vascular permeability. Jellinek 
and Detre suggested that increased systemic vascular 
permeability pre-dates development of atherosclerotic 
lesions. 54 Clinically, an increase in systemic vascular 
permeability is difficult o determine. However, there 
is good reason to correlate renovascular permeability 
with systemic vascular permeability. 55 Experimental 
work has shown that in hamsters ubjected to lap- 
arotomy and peritoneal contamination, there is an 
increase in microvascular permeability o fluorescein- 
labelled extran in the cheek pouch as well as increased 
urinary excretion of high molecular weight dextran. 56
Epidemiological evidence from the prospective Fram- 
ingham Study has also shown a three-fold increase in 
cardiovascular mortality in subjects with proteinuria. 57 
Excretion of urinary proteins may therefore reflect he 
amount of vascular endothelial damage and perhaps 
be indicative of the progression of atherosclerosis. 58'59 
Urinary albumin excretion is a useful measure of 
renovascular permeability. Physiologically, tubular e- 
sorption mechanisms for albumin are nearly saturated 
and therefore a small increase in vascular permeability 
will be amplified by the renal concentrating mech- 
anism leading to a significant increase in urinary 
albumin excretion - microalbuminuria. 46 Micro- 
albuminuria is defined as urinary albumin excretion, 
which is undetectable byqualitative dip-stix 55 and has 
been quantified as a urinary albumin concentration f 
15-200 mg/1. 6° Microalbuminuria is usually expressed 
as the albumin-creatine ratio (ACR) which allows for 
fluctuation in urinary flow rate. Microalbuminuria 
was originally described as an index of early diabetic 
nephropathy and later shown to be associated with 
pancreatitis, 61 the response to surgery, 62hypertension 63 
and adult respiratory distress syndrome following 
aortic surgery. 64 
The association between microalbuminuria and 
claudication has been well documented in several 
studies. Most studies have shown no significant dif- 
ference in the resting ACR between claudicants and 
controls, 46"52 although others have shown that the base- 
line ACR is higher in claudicants. 65'66 These results 
may be explained by the 100 to 1000-fold variation in 
ACR which would result in an elevated mean but 
perhaps not an elevated median ACR. All these studies 
have, however, shown a significant increase in ACR 
in claudicants following maximal treadmill exercise 
with no corresponding change in controls. Hickey 
demonstrated a 153% increase in ACR in 23 claudicants 
after treadmill exercise (p<0.001), with no significant 
change in 10 controlsY This exercise-induced increase 
in ACR has been shown to correlate with an increase 
in serum lipid peroxides, 46 total antioxidant con- 
sumption, 49neutrophil activation and degranulation 51,52 
and Doppler ankle pressure recovery time. 65 This char- 
acteristic increase in ACR with exercise may be used 
to assess the effect of treatment on claudication. Tsang 
showed that i week of treatment with oxypentifylline, 
which modulates vascular inflammation, led to a re- 
duction in the post-exercise increase in ACR compared 
to patients taking a placebo. 67 Surgery also appears to 
have an effect on the ACR. Hickey demonstrated that 
bypass surgery had no effect on the resting ACR in 
12 claudicants, but significantly attenuated the post- 
exercise rise in ACR. 51 Similar work by Matsushita et 
al. 66 confirmed these findings. 
An alternative method of assessing target organ 
damage in atherosclerosis is to measure plasma von 
Willebrand factor (vWF). vWF is a specific product of 
damaged vascular endothelial cells and has a role in 
platelet aggregation and adhesion. 6sElevated vWF has 
been demonstrated in subjects with known cardio- 
vascular isk factors such as diabetes, hypertension, 
smoking and hypercholesterolaemia. 69 A significant 
increase in vWF has also been shown in subjects 
with PAD compared to controls, presumably due to 
repetitive low-grade inflammatory events. 7°'7~ As with 
urinary albumin, vWF has been shown to increase 
following treadmill exercise in claudicants. 48 
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The studies detailed above provide conclusive vid- 
ence that exercise in claudicants i  associated with an 
inflammatory response with free radical formation, 
lipid peroxidation, deficient antioxidant mechanisms, 
neutrophil activation, eicosanoid synthesis and vas- 
cular endothelial damage. The significance of these 
changes is not fully understood. Repeated low-grade 
inflammatory events, however, may lead to pro- 
gression of atherosclerosis, 72 perhaps explaining the 
excess cardiovascular mortality in these patients. Pro- 
teinuria and the neutrophil count are certainly known 
to be predictive of future cardiovascular events. 57'73 
Exercise-induced inflammation i  the pathogenesis of 
atherosclerosis 
Lipid peroxides, generated in claudicants from ex- 
ercise-induced IRI, have been suggested as in- 
dependent risk factors for the progression of 
atherosclerosis. 47 Lipid peroxides are cytotoxic to vas- 
cular endothelium, procoagulant and may promote 
platelet activation. More recently it has been noted 
that lipid peroxides are able to oxidise subendothelial 
low-density lipoprotein (LDL) to various grades of 
oxidised LDL (OX-LDL). Oxidation mainly occurs 
within the arterial intima, as circulating antioxidants 
such as vitamin E prevent significant intravascular 
oxidation of LDL. 74'75 The various oxidised LDLs are 
cytotoxic to vascular endothelium, thrombogenic, im- 
munogenic and recruit macrophages into the sub- 
endothelial spacer 6"77 Increasing evidence suggests that 
macrophages play an important role in the de- 
velopment of atherosclerosis. 72'7s'79 Immune complexes, 
formed by antibodies to epitopes of OX-LDL, 75 and 
OX-LDL itself are taken up by "scavenger receptors" 
on macrophages, resulting in unregulated ac- 
cumulation of cholesterol and lipid debris forming the 
characteristic "foam cells" of atherosclerosis, s° Ox- 
idised lipid may also induce macrophages to release 
cytokines which initiate an hepatic acute-phase re- 
sponse 75's~ (Fig. 4). It has been suggested that cytokines 
themselves are atherogenic, although induction of hep- 
atic synthesis of fibrinogen and other acute-phase 
proteins may be a more likely explanation. 
Measurement ofacute-phase proteins may therefore 
provide an opportunity to assess the intermediate-term 
effect of repeated inflammatory episodes as occurs in 
claudication. Persisting elevation of acute-phase l vels 
may also reflect he systemic nature of the disease and 
possibly explain the excess cardiovascular mortality 
in these patients. 8a Alternative theories have been pro- 
posed to explain the association between acute-phase 
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Fig. 4. The role of lipid peroxidation i  oxidation of low-density 
lipoprotein and acute-phase protein synthesis. (OX-LDL = oxidised 
low-density lipoprotein, CRP=C-reactive protein, SAA=serum 
amyloid A protein). 
protein synthesis and atherogenesis. Khaw and 
Woodhouse suggested that repeated exposure to en- 
vironmental inflammatory stimuli, such as respiratory 
infection, results in macrophage activation and syn- 
thesis of acute-phase proteins, such as fibrinogen, 
which have atherogenic potential, s3 However, the re- 
sponse to oxidised lipids appears to be a more logical 
hypothesis, although both theories recognise the 
importance of acute-phase proteins in atherosclerosis. 
Fibrinogen. There is now impressive vidence that fib- 
rinogen is an important cardiovascular risk factor. The 
Framlingham, Northwick Park and Caerphilly studies 
demonstrated that an elevated fibrinogen at baseline 
was an important prognostic factor for incident isch- 
aemic heart disease. 8446 The Speedwell prospective 
heart disease study also showed that a raised fib- 
rinogen predicted the development ofintermitten clau- 
dication. 15 Both hospital and population-based studies 
in claudicants have shown an elevated fibrinogen in 
claudicants compared to controls, 7 Recent work from 
the Edinburgh Artery Study has also shown an increase 
in fibrinogen degradation products (FDP) (urinary 
fibrinopeptide A and plasma D-dimer) in claudicants 
compared to controls, s8 This study also found an in- 
dependent association between fibrinogen and a re- 
duction in the Doppler ankle-brachial pressure index. 89 
Claudicants with a raised fibrinogen are known to 
have poor prognosis in terms of local progression of 
disease, 9°graft failure 91 and cardiovascular death. 9a 
The mechanisms ofaction of fibrinogen are complex. 
Undoubtedly, fibrinogen adversely affects micro- 
circulatory blood flow via its influence on red cell 
platelet activation, activation of coagulation mech- 
anisms and increased plasma viscosity. Recent work 
has also suggested that fibrinogen and LDL have 
common uptake into atherosclerotic plaque, where 
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fibrinogen is converted to fibrin with subsequent fib- 
rinolysis. FDPs may be atherogenic via effects on 
smooth muscle cell proliferation, increased micro- 
vascular permeability and neutrophil chemotaxis. 9s'94 
Some recent work has, however, suggested that an 
elevated fibrinogen in atherosclerosis may not be a 
consequence of repeated acute-phase responses, but 
may result from genetic polymorphism, producing a 
protein with abnormal atherogenic potential. 95'96 In 
considering this work and the notorious difficulty in 
interpreting a single fibrinogen result, 97 alternative 
markers of the acute-phase r sponse may have greater 
value in assessing the inflammatory status in clau- 
dicants. 
C-reactive protein. C-reactive protein (CRP) has im- 
portant potential use as a marker of repeated in- 
flammatory events in claudication. CRP is synthesised 
by hepatocytes in response to interleukin-6 derived 
from macrophages 98 and, as there is no tissue de- 
positon, the serum level reflects the synthetic rate. 99 
Rather than acting as a passive marker of athero- 
sclerosis, CRP has the ability to activate the classical 
complement pathway ~°° and may lead to platelet ag- 
gregation and release reactions. In vitro work has also 
suggested that CRP complexed to damaged endo- 
thelial cells may selectively bind LDL, which obviously 
has important implications for atherogenesis. ~°1
There is little published work on the measurement 
of CRP in peripheral arterial disease (PAD). Majewski 
showed that CRP progressively increased according 
to the Fontaine staging of PAD, with patients with 
critical ischaemia having significantly greater CRP 
levels than claudicants. ~°2 In the 20 claudicants in this 
study the median CRP was I mg/l: the 90th percentile 
of the normal range has been quoted as 3 mg/1. ~°s The 
apparently normal values may have been due to the 
relatively insensitive assay used which had a limit of 
detection of 5 mg/1. In another study of 929 patients 
admitted to a coronary rehabilitation unit, significantly 
higher CRP levels were found in patients with co- 
existent PAD, although again these were within the 
normal range. 94 It was suggested that small increments 
within the normal range represented significant in- 
flammatory events. In support of the environmental 
inflammatory aetiology of atherosclerosis, a recent 
study has shown an increased CRP in those previously 
exposed to Helicobacter pylori and chlamydia pneu- 
monia infection, and that this elevated CRP was as- 
sociated with prevalent intermittent claudication. TM 
We have previously shown that the CRP level in 44 
stable claudicants ignificantly correlates with both 
plasma fibrinogen and the urinary ACR, providing a 
link between ischaemia-reperfusion nduced increase 
in vascular permeability and the resulting acute-phase 
response. 1°5 
The association between CRP and ischaemic heart 
disease (IHD) has received more attention, although 
CRP does not appear to correlate with the severity of 
the presenting IHD but rather with future cardiac 
risk. 1°6 The European Concerted Action on Thrombosis 
and Disabilities Angina Pectoris (ECAT) study showed 
that a raised CRP within the normal range in patients 
with stable angina was prognostic for myocardial in- 
farction and cardiac death. 1°7 In patients with unstable 
angina, a CRP>3 mg/1 has also been shown to predict 
a poor response to  medical treatment and re-in- 
farction. ~°8 The above studies suggest that CRP is 
elevated in claudicants, although remaining within the 
normal range, and that a raised CRP may be considered 
as an adverse cardiovascular risk factor. However, its 
use may be limited by the fact that a sensitive assay 
is required to detect any small changes from normal. 
Serum amyloid A protein. Serum amyloid A protein 
(SAA) has potential use as a very sensitive marker of 
the acute-phase r sponse, with serum levels increasing 
up to 1000 times the physiological value following an 
inflammatory response. 1°9 The function of constitutive 
SAA (SAA4) is unknown, although it does not increase 
in response to oxidised lipids. 11° Acute-phase SAA 
(SAA1 and SAA 2~/2J3) is structurally an apolipo- 
protein and is synthesised by hepatocytes in response 
to cytokines, predominantly interleukin-1. ~1'112 Recent 
experimental work has also shown that all the im- 
portant cell-types in atherosclerosis-macrophages - 
vascular endothelial cells and smooth muscle cells - 
express messenger RNA and therefore the ability to 
synthesise SAA.  113'114 
The physiological effects of SAA are intrinsically 
linked with high-density lipoprotein (HDL) meta- 
bolism that has important protective ffects via the 
"reverse cholesterol transport" mechanism. ~5 SAA ap- 
pears to have both pro-atherogenic and anti-athero- 
genic functions, suggesting complex control 
mechanisms are operating. SAA displaces apolipo- 
protein A-I from HDL, reducing HDUs lecithin cho- 
lesterol acyl transferase activity, which has the net 
effect of increasing cholesterol deposition at sites of 
endothelial injury, where it may be taken up by LDL. 116 
SAA bound to HDL reduces the hepatocyte affinity 
for HDL and downregulates hepatocyte expression of 
the HDL receptor, while increasing HDL's affinity for 
subendothelial macrophages and increasing macro- 
phage expression of the HDL receptorY The net result 
is accumulation of the SAA-HDL complex in the sub- 
endothelium where SAA is then deposited, leaving 
HDL free to scavenge cholesterol debris released from 
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macrophages. In keeping with its "schizophrenic" 
function, SAA has been shown to inhibit the neutrophil 
oxidative burst, inhibit platelet aggregation and release 
reactions, m suppress macrophage T-cell interaction 1°° 
and induce chemokinesis of monocytes and neutro- 
phils. Ha SAA also upregulates expression of the Mac- 
1 neutrophil adhesion molecule] 19 The overall effect 
of SAA therefore appears to be to direct both in- 
flammatory cells and HDL to the site of endothelial 
injury where lipid debris can be dealt with effectively. 
In view of these mechanisms, it therefore seems 
appealing to measure SAA level as an index of the 
inflammatory response in atherosclerotic plaque. To 
date, no work has previously been published on SAA 
in peripheral arterial disease. Limited studies have 
measured SAA in ischaemic heart disease. Un-  
surprisingly, SAA is known to rise following myo- 
cardial infarction, due to the marked acute-phase 
response. 12° However, Liuzzo showed that in patients 
with unstable angina, an elevated SAA was predictive 
of further cardiovascular morbidity and mortality. 1°8 
Conclus ion 
Current opinion suggests that patients with in- 
termittent claudication should be encouraged to take 
regular exercise. Clinical trials of exercise training have 
shown an undoubted benefit in terms of walking 
distance and quality of life. Exercise is also known to 
benefit cardiovascular health in the general population. 
However, claudicants have excessive cardiovascular 
morbidity and mortality rates compared to the general 
population. There is overwhelming experimental evid- 
ence that in claudicants, exercise to the onset of calf 
pain followed by rest results in an ischaemia-re- 
perfusion insult with free radical formation, neutrophil 
activation and systemic vascular endothelial damage. 
Increasing evidence also suggests that repetitive low- 
grade inflammatory episodes may lead to progression 
of atherosclerosis, which may explain the increased 
incidence of ischaemic heart disease and stroke in 
these patients. Further studies are need to clarify the 
nature of this inflammatory response in relation to 
exercise, perhaps by measurement of more stable 
markers of inflammation such as acute-phase proteins. 
This will help determine whether these biochemical 
changes have any clinical significance. The un- 
answered question is whether exercise training leads 
to a cumulative increase in the inflammatory response 
or whether, by increasing the pain-free walking dis- 
tance, the effect of each individual ischaemia-re- 
perfusion event is decreased. We have, in fact, recently 
shown that exercise training leads to a reduction in 
these biochemical markers of inflammation, m There 
is therefore no clinical evidence to suggest that subjects 
with intermittent claudication should be discouraged 
from exercising: further experimental work may in 
fact confirm that exercise training decreases the in- 
flammatory response to walking. This may have bene- 
ficial effects in terms of progression of atherosclerosis. 
References  
1 HOUSLE¥ E. Treating claudication i  five words. Br Med J 1988; 
296: 1483-1484. 
2 HOUSLEY E, LENG GC, DONNAN PT, FOWKES FG. Physical activity 
and risk of peripheral arterial disease in the general population: 
Edinburgh Artery Study. J Epidemiol Community Health 1993; 
47: 475-480. 
3 POWELL E, PRATT M. Physical activity and health. Br Med J 
1996; 313: 126-127. 
4 SECRETARY OF STATE FOR HEALTH. The Health of the Nation. A 
strategy for health in England. HMSO: London, 1992; 46-7, 62-4. 
5 ERNST E. Exercise: the best herapy for intermittent claudication? 
Br J Hosp Med 1992; 48: 303-307. 
6 LARSEN OA, LASSEN NA. Effect of daily muscular exercise in 
patients with intermittent claudication. Lancet 1966; ii: 1093- 
1095. 
7 ERICSSON B, HAEGER K, LINDELL SE. Effect of physical training 
on intermittent claudication. Angiology 1970; 21: 188-192. 
8 DAHLLOF AG, BJORNTORP P, HOLM J, SCHERSTEN T. Metabolic 
activity of skeletal muscle in patients with peripheral arterial 
insufficiency. Eur J Clin Invest 1974; 4: 9-15. 
9 DAHLLOr AG, HOLM J. Peripheral arterial insufficiency. Effect 
of physical training on walking tolerance, calf blood flow and 
blood resistance. Scand J Rehab Med 1976; 8: 19-26. 
10 HIATT WR; REGENSTEINER J, HARGARTEN ME, WOL~EN EE. 
Benefit of exercise conditioning for patients with peripheral 
arterial disease. Circulation 1990; 81: 602-609. 
11 GARDNER AW, POEHLMAN ET. Exercise rehabilitation programs 
for the treatment of claudication pain. A meta-anatysis. JAMA 
1995; 274: 975-980. 
12 CREASY TS, McMILLAN PJ, FLETCHER EWL, COLLIN J, MORRIS 
PJ. Is percutaneous transluminal angioplasty better than ex- 
ercise for claudication? Preliminary results from a prospective 
randomised trial. Eur J Vasc Surg 1990; 4: 135-140. 
13 PERKINS JMT, COLLIN J, GREASY TS, FLETCHER EWL, MORRIS 
PJ. Exercise training versus angioplasty for stable claudication: 
long and medium term results of a prospective randomised 
trial. Eur f Vasc Endovasc Surg 1996; 11: 409-413. 
14 DORMANDY IA, MAHIR M, ASCADY G, BALSANO 1 ~, DE LEEUW P. 
Fate of the patient with chronic leg ischaemia. J Cardiovasc Surg 
1989; 30: 50-57. 
15 BAINTON D, SWEETNAM P, BAKER I, ELWOOD P. Peripheral vas- 
cular disease: consequence for survival and association with 
risk factors in the Speedwell prospective heart disease study. 
Br Heart J 1994; 72: 128-132. 
16 HOLM J. The effect of exercise on intermittent claudication. In: 
Bell PRF, Jamieson CW, Ruckley CV, eds. Surgical Management 
of Vascular Diseases. Saunders: Lo~tdon, 1992; 111-118. 
17 HAIMOVlCI H. Muscular, renal and, metabolic omplications of
acute arterial occlusions: myonephropathic-metabolic syn- 
drome. Surgery 1979; 85: 461-468. 
18 PARKS DA, GRANGER DN. Contributions of ischemia and re- 
perfusion to mucosal esion formation. Am J Physiol 1986; 250: 
G749-G753.. 
19 CAILLARD P, MOUREN X, PUJADE B, BLANCHEMAISON P, ELBEZE 
Y/ CLOAREC M. Objectifying ~xercise ischaemia in peripheral 
Eur J Vasc Endovasc Surg Vol 15, January 1998 
Exercise-induced Inflammation in Intermittent Claudication 15 
vascular disease: a study in 120 patients. Angiology 1990; 12: 
469-478. 
20 McCORD JM. Ocygen-derived free radicals in postischemic 
tissue injury. N Engl J Med 1985; 312: 159-163. 
21 WINDSOR ACJ, MULLEN PG, FOWLER AA, SUGERMAN HJ. Role 
of the neutrophil in adult respiratory distress yndrome. Br J 
Surg 1993; 80: 10-17. 
22 LELCUK S, ALEXANDER F, VALERI R, SHEPRO D, HECHTMAN H. 
Thromboxane A2 moderates permeability after limb ischaemia. 
Ann Surg 1985; 202: 642-646. 
23 HOMER-VANNIASINKAM S, GOUGH MJ. Role of lipid mediators 
in the pathogenesis of skeletal muscle infarction and oedema 
during reperfusion after ischaemia. Br J Surg 1994; 81:1500-1503. 
24 SINCLAIR aJ, BARNETT AH, LUNEC J. Free radicals and anti- 
oxidant systems in health and disease. Br J Hosp Med 1990; 43: 
344-341. 
25 PARKS DA, BULKLEY GB, GRANGER DN. Role of oxygen free 
radicals in shock, ischemia and organ preservation. Surgery 
1983; 94: 428-438. 
26 PATERSON IS, KLAUSNER JM, GOLDMAN Get  al. Pulmonary 
edema after aneurysm surgery is modified by mannitol. Ann 
Surg 1989; 210: 796-801. 
27 PATERSON IS, CORSON J, McCOLLUM CN, GOLDMAN MD, 
MIDDLETON MD. Activated neutrophils mediate multiple organ 
dysfunction following aortic aneurysm repair. Br J Surg 1992; 
76: 358. 
28 PATERSON IS, SMITH FC% TSANG GMK, HAMER JD, SHEARMAN 
CP. Reperfusion plasma contains a neutrophil activator. Ann 
Vasc Surg 1993; 7: 68-75. 
29 HICKMAM P, McCOLLUM PT, BELCH JJE Neutrophils may con- 
tribute to the morbidity and mortality of claudicants. Br J Surg 
1994; 81: 790-798. 
30 KLAUSNER JM, PATERSON IS, MANNICK JA, VALERI CR, SHEPRO 
D, HECHTMAN HB. Reperfusion pulmonary edema. JAMA 1989; 
261: 1030-1035. 
31 BENGTSON A, HOLMBERG P~ HEIDEMAN M. The ischaemic leg as 
a source of complement activation. Br J Surg 1987; 74: 697-700. 
32 NEUMANN FJ, WAAS W, DIEHM C et al. Activation and decreased 
deformability of neutrophils after intermittent claudication. 
Circulation 1990; 82(3): 922-929. 
33 BAGGIOLINI M, WALZ A, KUNKEL SL. Neutrophil activating 
peptide-1/Interleukin 8, anovel cytokine that activates neutro- 
phils. J Clin Invest 1989; 84: 1045-1049. 
34 GROSS V, ANDREESEN R, LESER HG, CESKA M. Interleukin-8 and 
neutrophil activation in acute pancreatitis. Eur ] Clin Invest 
1992; 22: 200-203. 
35 FURCHGOTT RE, ZAWADZKI JV. The obligatory role of endothelial 
cells in the relaxation of arterial smooth muscle by acetycholine. 
Nature 1980; 288: 373-376. 
36 PALMER R2~J, FERRIGE AG, MONCADA S. Nitric oxide release 
accounts for the biological activity of endothelium-derived 
relaxing factor. Nature 1987; 327: 524-526. 
37 VALLANCE P, COLLIER J. Biology and clinical relevance of nitric 
oxide. Br Med J 1994; 309: 453-459. 
38 DAVIES MG, FULTON GJ, HAGEN PO. Clinical biology of nitric 
oxide. Br J Surg 1995; 82: 1598-1610. 
39 WEIGHT SC, BELL PRF, NICHOLSON ML. Renal ischaemia-re- 
perfusion injury. Br J Surg 1996; 83: 162-170. 
40 GRACE P. Ischemia-reperfusion njury. Br J Surg 1994; 81: 637- 
647. 
41 VANE JR, ANGGARD EE, BOTTING RM. Regulatory functions of 
the vascular endothelium. N Eng J Med 1990; 323: 27-36. 
42 HAYNES WG, WEBB DJ. The endothelin family of peptides: local 
hormones with diverse roles in health and disease? Clin Sci 
1993; 84: 485-500. 
43 EDWARDS JD, DOVGAN PS, ROWLEY JM, AGRAWAL DK, THORPE 
PE, ADRIAN TE. Endothelin-1 levels in ischaemia, reperfusion 
and haemorrhagic shock in the canine infrarenal aortic re- 
vascularization model. Eur J Vasc Surg 1994; 8: 729-734. 
44 HiCRMAN P, HAItRIsoN DK, HILL A et aL Exercise in patients with 
intermittent claudication results in the generation of oxygen 
derived free radicals and endothelial damage. Adv Exp Med BioI 
1994; 36: P565-P570. 
45 HICKMAN P, MCCLAREN M, HILL H, McCOLLUM PR, BELCH JJ. 
Exercise causes endothelial damage in claudicants but in healthy 
controls. Br J Surg 1994; 81: 616. 
46 SI~EARMAN CP, GOSLING Pr GWYNN BR, SIMMS MH. Systemic 
effects associated with intermittent claudication. A model to 
study biochemical spects of vascular disease? Eur J Vasc Surg 
1988; 2: 401-404. 
47 STRINGER MD, GOROG PG, FREEMAN A, KAKKAR MY. Lipid 
peroxides and athersclerosis. BrMed J 1989; 298: 281-284. 
48 EDWARDS AT, BLANN AD, SUAREZ-MENDEZ VJ. Systemic re- 
sponses in patients with intermittent claudication after treadmill 
exercise. Br J Surg 1994; 81: 1738-1741. 
49 KHAIRA HS, MAXWELL SRJ, SHEARMAN CP. Antioxidant con- 
sumption during exercise in intermittent claudication. Br J Surg 
1995; 82: 1660-1662. 
50 CRINNION IN, HOMER-VANNIASINKAM S, PARKIN SM, GOUGH 
MJ. The role of neutrophil-endothelial adhesion in skeletal 
muscle reperfusion injury. Br J Surg 1996; 83: 251-254. 
51 HICKEY NC, GOSLING P, BAAR S, SHEARMAN CP, SIMMS MH. 
Effect of surgery on the systemic inflammatory response to 
intermittent claudication. Br J Surg 1990; 77: 1121-1124. 
52 KHAIRA HS, NASH GB, BAHRA PS et al. Thromboxane and 
neutrophfl changes following intermittent claudication suggest 
ischaemia-reperfusion injury. Eur J Vase Endovasc Surg 1995; 10: 
31-35. 
53 WENNMALM A, EDLuND A, SEVASTIK B, FITZGERALD A. Excretion 
of thromboxane A2 and prostacyclin metabolites during tread- 
mill exercise in patients with intermittent claudication. Clin 
Physiol 1988; 8: 243-252. 
54 JELLINEK H, DETRE Z. Role of the altered transmural per- 
meability in the pathomechanism of arteriosclerosis. Part I. 
History of arteriosclerosis theories. Path Res Pract 1986; 181: 
693-712. 
55 WINOCOUR PH. Microalbuminuria. Br Med J 1992; 304: 1196- 
1197. 
56 SHEARMAN CP I GOSLING PI SIMMS MH. Glomerular permeability 
to large molecules: a marker of vascular permeability? Br f Surg 
1988; 75: 1273. 
57 KANNEL WB, STAMPFER MJ, CASTELLI WE, VERTER J, The pro- 
gnostic significance of proteinuria: the Framingham study. Am 
Heart J 1984; 108: 1347-1352. 
58 GOSLING P, SHEARMAN CP. Increased levels of urinary proteins: 
markers of vascular permeability? Ann Clin Biochem 1988; 25 
(Suppl.): $150-$151. 
59 GOSLING Pr BEEVERS DG, GOODE GE, HICKEY NC, LITTLER WA, 
SHEARMAN CP. Lancet 1990; 335: 349-350. 
60 WATTS GF, BENNETT JE, ROWE DJ et al. Assessment of im- 
munochemical methods for determining low concentrations of 
albumin in urine. Clin Chem 1986; 32: 1544-1548. 
61 SHEARMAN CPI GOSLING P, WALKER KJ. Is low proteinuria n 
early predictor of severity of acute pancreatitis? J Clin Pathol 
1989; 42: 1132-1135. 
62 GOSLING P, StIEARMAN CPl GWYNN BR, SIMMS MH, BAINBRIDGE 
ET. Microproteinuria: response to operation. Br J Med 1988; 296: 
338-339. 
63 GOSLING P, BEEVERS DG. Urinary albumin excretion and blood 
pressure in the general population. Clin Sci 1989; 76: 39-42. 
64 SMITH EC% GOSLING P, SANGHERA K, GREEN MA, PATERSON 
IS, SHEARMAN CP. Microproteinuria predicts the severity of 
systemic effects of reperfusion i jury following infrarenal aortic 
aneurysm surgery. Ann Vasc Surg 1994; 8: 1-5. 
65 HICKEY NC, SHEARMAN CP, GOSLING P, SIMMS MH. Assessment 
of intermittent claudication of exercise-induced micro- 
albuminuria. Eur ] Vasc Surg 1990; 4: 603-606. 
66 MATSUSHITA M, NISHIKIMI N, SAKURAI % YANO T, NIMURA Y. 
Urinary microalbumin as a marker for intermittent claudication. 
Eur ] Vasc Endovasc Surg 1996; 11: 421-424. 
67 TSANC GM, SANGI-IERA K, GOSLING Pet  al. Pharmacological 
Eur J Vasc Endovasc Surg Vol 15, January 1998 
16 P.V. Tisi and C. P. Shearman 
reduction of the systemically damaging effects of local isch- 
aemia. Eur J Vasc Surg 1994; 8: 205-208. 
68 BLANN AD. von Willebrand factor as a marker of injury to the 
endothelium in inflammatory vascular disease. J Rheumatol 
1993; 20: 1469-1471. 
69 BLANN AD, McCOLLUM CN. von Willebrand factor, endothelial 
cell damage and atherosclerosis. Eur J Vasc Surg 1994; 8: 10-15. 
70 BLANN AD, McCOLLUM CN. Circulating endothelial cell/leu- 
kocyte adhesion molecules in atherosclerosis. Thromb Haemost 
1994; 72: 151-154. 
71 BLANN AD, DOBROTOVA M, KUBISZ P, McCOLLUM CN. von 
Willebrand factor, soluble P-selectin, tissue plasminogen ac- 
tivator and plasminogen activator inhibitor in atherosclerosis. 
Thromb Haemost 1995; 74: 626-630. 
72 Ross R. The pathogenesis of atherosclerosis: a perspective for 
the 1990s. Nature 1993; 362: 801-809. 
73 ERNST EE, HAMMERSCHMIDT DE, BAGGE U, MATRAI A, 
DORMANDY JA. Leukocytes and the risk of ischaemic diseases. 
]AMA 1987; 257: 2318-2324. 
74 LEAKE DS. Oxidised low density lipoproteins and atherogenesis. 
Br Heart J 1993; 69: 476-478. 
75 WITZtTM JL. The oxidation hypothesis of atherosclerosis. Lancet 
1994; 344: 793-795. 
76 WITZUM JL, STEINBERG D. Role of oxidised low density lipo- 
protein in atherogenesis. J Clin Invest 1991; 88: 1785-1792. 
77 LIAO F, ANDALIBI A, LUSlS AJ, FOGELMAN AM. Gentic control 
of the inflammatory response induced by oxidised lipids. Am 
f Cardiol 1995; 75: 65B-66B. 
78 Gown AM, TSUKADA T, Ross R. Human atherosclerosis. II. 
Immunocytochemical analysis of the cellular compositon of 
human atherosclerotic lesions. Am J Path 1986; 125: 191-207. 
79 Ross R. The pathogenesis of atherosclerosis - an update. N 
EngI J Med 1986; 314: 488-500. 
80 MITCtIINSON MJ, BALL RY. Macrophages and atherogenesis. 
Lancet 1987; 2: 146-148. 
81 HEINRICH PC, CASTELL JV, ANDUS T. Interleukin-6 and the acute 
phase response. Biochem f 1990; 265: 621-636. 
82 STUART J. The acute-phase r action and haematological stress 
syndrome in vascular disease, hzt f Microcirc 1984; Clin Exp 3: 
115-129. 
83 KHAW KT, WOODMOUSE P. Interrelation of vitamin C, infection, 
haemostatic factors and cardiovascular disease. Br J Med 1995; 
310: 1559-1562. 
84 KANNEL WB, WOLF PA, CASTELLI WP, D'AGOSTINO RB. Fib- 
rinogen and risk of cardiovascular disease. The Framingham 
Study. JAMA 1987; 258: 1183-1186. 
85 MEADE T~vV, BROZOVIC M, CHAKRABARTI RR, HAINES AP, IMESON 
JD. Haemostatic function and ischaemic heart disease: principal 
results of the Northwick Park Heart Study. Lancet 1986; 2: 
533-537. 
86 YARNELL JWG, BAKER Ia, SWEETNAM PM, BAINTON D. Fib- 
rinogen, viscosity and white blood cell count are major risk 
factors for ischaemic heart disease. Circulation 1991; 83: 836-844. 
87 FOWKES FG. Fibrinogen and peripheral arterial disease. Eur 
Heart J 1995; 16 (Suppl. A): 36-40. 
88 LEE AJ, FOWKES FGR, RATTRAY A, RUMLEY A, LOWE GDO. 
Haemostatic and theological factors in intermittent claudication: 
the influence of smoking and extent of arterial disease. Br J 
Haem 1996; 92: 226-230. 
89 LowE GD, FOWKES FG, DAWES J, DONNAN PT, LENNIE SE, 
HOUSLEY E. Blood viscosity, fibrinogen, and activation of co- 
agulation and leukocytes in peripheral arterial disease and the 
normal population in the Edinburgh Artery Study. Circulation 
1993; 87: 1915-1920. 
90 DORMANDY JA, HOARE E, KHATTAB AH, ARROWSMITH DE, 
DORMANDY TL. Prognostic significance of rheological and bio- 
chemical findings in patients with intermittent claudication. Br 
Med J 1973; 4: 581-583. 
91 HAMER JD, ASHTON F~ MEYNELL MJ. Factors influencing pro- 
gnosis in the surgery of peripheral vascular disease: platelet 
adhesiveness, plasma fibrinogen and fibrinolysis. BrJ Surg 1973; 
60: 386-389. 
92 BANERJEE AK, PEARSON J, GILLILAND EL et aI. A six-year 
prospective study of fibrinogen and other isk factors associated 
with mortality in stable claudicants. Thromb Haemost 1992; 68: 
261-263. 
93 SMITH EB, K~N GA, GRANT A, STIRK C. Fate of fibrinogen in 
human arterial intima. Arteriosclerosis 1990; 10: 263-275. 
94 HEINRICH J, SCHULTE H, SCHONEELD R~ KOHLER E, ASSMAN G. 
Association of variables of coagulation, fibrinolysis and acute- 
phase with atherosclerosis in coronary and peripheral arteries 
and those arteries upplying the brain. Thromb Haemost 1995; 
73: 374-379. 
95 HAMSTEN A, DE FAIRE U, ISELIUS L, BLOMBAO M. Genetic and 
cultural inheritance of plasma fibrinogen concentration. Lancet 
1987; 2: 988-990. 
96 FOWKES FGR, CONNOR JM, SMITH FB, WOOD J, DONNAN PT, 
LOWE GDO. Fibrinogen genotype and risk of peripheral athero- 
sclerosis. Lancet 1992; 339: 693-696. 
97 MACHIN SJ, MACKIE IJ. Routine measurement of fibrinogen 
concentration. Br Med J 1993; 307: 882-883. 
98 CRUIKSHANK AM, FRASER WD, BURNS HJG, VAN DAMME J, 
SHENKIN A. Response of serum interleukin-6 in patients under- 
going elective surgery of varying severity. Clin Sci 1990; 79: 
161-165. 
99 PEPYS MB. Rheumatoid arthritis: the role of acute-phase pro- 
teins. Br J Rheumatol 1993; 32 (Suppl. 3): 1-2. 
100 KUSHNER I, GEWURZ H, BENSON MD. C-reactive protein and 
the acute-phase r sponse. J Lab Clin Med 1981; 97: 739-749. 
101 PEPYS MB, BALTZ ML. Acute phase proteins with special ref- 
erence to C-reactive protein and related proteins (pentaxins) 
and serum amyloid A protein. Adv Immunol 1983; 34: 141-212. 
102 MAJEWSKI W, ZIELINSKI A, LACIAK Met aI. C-reactive protein 
and alpha-l-acid glycoprotein in monitoring of patients with 
chronic arterial occlusion of the lower limbs. Eur J Vasc Surg 
1993; 7: 628-623. 
103 WrLKINS J, GALLIMORE JR, TENNENT GA et al. Rapid automated 
enzyme immunoassay ofserum amyloid A. Clin Chem 1994; 40: 
1284-1290. 
104 MENDALL MA, PATEL P, STRACHAN D, NORTH]FIELD TC. C 
Reactive protein and its relation to cardiovascular risk factors: 
a population based cross sectional study. Br Med J 1996; 312: 
1061-1065. 
105 TIsI PV, CRow AJ, S~EARMAN CP. The use of inflammatory 
markers in the assessment of intermittent ciaudication. Eur Surg 
Res 1996; 28 (Suppl. 1): 65. 
106 MAS~RI A, BIASUCCI LM, LIuzzo G. Inflammation i  ischaemic 
heart disease. Br Med J 1996; 312: 1049-1050. 
107 T~OMPSON SG, KIENAST J, PYKE SDM, HAVERKATE E VAN DE 
LOO JCW. Haemostatic factors and the risk of myocardial 
infarction or sudden death in patients with angina pectoris. N 
Engl f Med 1995; 332: 635-641. 
108 LI•zzo G, BIAsUCCI LM, GALLIMORE JR et al. The prognostic 
value of C-reactive protein and serum amyloid a protein in 
severe unstable angina. N Engl J Med 1994; 331: 417-424. 
109 IK/IAURY CPJ. Comparative study of serum amyloid A protein 
and C-reactive protein in disease. Clin Sci 1985; 68: 233-238. 
110 LIAO F, ANDALIBI A, QIAO JH, ALLAYEE H, FOGELMAN AM, 
LUSlS AJ. Genetic evidence for a common pathway mediating 
oxidative stress, inflammatory gene induction and aortic fatty 
streak formation in mice. J Clin Invest 1994; 94: 877-884. 
111 MALLE E, STEINMETZ A, RAYN~S JG. Serum amyloid A (SAA): 
an acute phase protein and apolipoprotein. Atherosclerosis 1993; 
102: 131-146. 
112 RAYNES JG, EAGLING S, MCADAM KP. Acute-phase protein 
synthesis in human hepatoma cells: differential regulation of 
serum amyloid A (SAA) and haptoglobulin by interleukin-1 
and interleukin-6. Ctin Exp Immunol 1991; 83: 488-491. 
113 URIELI-SHOVAL S, MEEK RL, HANSON RH, ERIKSEN N, BENDITT 
EP. Human serum amyloid A genes are expressed inmonocyte/ 
macrophage cell lines. Am J Pathol 1994; 145: 650-660. 
Eur J Vasc Endovasc Surg Vol 15, January 1998 
Exercise-induced Inflammation in Intermittent Claudication 17 
114 MEEK RL, URIELI-SHOVAL S, BENDITT EP. Expression of apolipo- 
protein serum amyloid A mRNA in human atherosclerotic 
lesions and cultured vascular cells: implications for serum 
amyloid A function. Proc NatI Acad Sci U.S.A. 1994; 91: 3186- 
3190. 
115 GORDON DJ, RIEKIND BM. High-density lipoprotein - the clinical 
implications of recent studies. N Engl JMed 1998; 321: 1311-1316. 
116 BLACKBURN WDJ. Validity of acute phase proteins as markers 
of disease activity. J Rheumatol Supp 1994; 42: 9-13. 
117 KISILEVSKY R, SLTBRAFIMANYAN L. Serum amyloid A changes 
high density lipoprotein's cellular affinity. A clue to serum 
amyloid A's principal function. Lab Invest 1992; 66: 778-785. 
118 Xu L, BADOLATO R, MURPHY WJ et al. A novel biologic function 
of serum amyloid A. Induction of T-lymphocyte migration and 
adhesion. J ImmunoI 1995; 155: 1184-1190. 
119 BADOLATO R~ WANG JM, MURPHY WJ et al. Serum amyloid A is 
a chemoattractant: i duction of migration, adhesion, and tissue 
infiltration of monocytes and polymorphonuclear leukocytes. J 
Exp Med 1994; 180: 203-209. 
120 MAURY CPJ, TOTTERMAN KJ, GREF CG, EHNHOLM C. Serum 
amyloid A protein, apolipoprotein A-I and apolipoprotein B 
during the course of acute myocardial infarction. J Clin Path 
1988; 41: 1263-1268. 
121 TIsI PV, H~LS~ M, CHULAKADABBA A, GOSLING P, SHEARMAN CP. 
Exercise training for intermittent claudication: does it adversely 
affect biochemical markers of the exercise-induced in- 
flammatory response? Eur J Vasc Endovasc Surg 1997; 14: 344- 
350. 
Accepted 23 July 1997 
Eur J Vasc Endovasc Surg Vol 15, January 1998 
